Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for Prevention of Postoperative Nausea and Vomiting After Bariatric Surgery
2023-508849-40-00Phase 4Authorised
- Sponsor
- University of Tartu
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in postoperative nausea and vomiting (PONV) comparing Aprepitant with Placebo (2 arms). Primary endpoints: Incidence of postoperative nausea and vomiting (PONV), Severity of PONV and 1 more. Planned start Apr 2024; status: authorised.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on 2023-508849-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508849-40-00.